Added to YB: 2024-12-23
Pitch date: 2024-12-18
GALT [bearish]
Galectin Therapeutics Inc.
-209.41%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.
Market Cap
$82.2M
Pitch Price
$2.02
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.10
P/E
-1.80
EV/Sales
N/A
Sector
Biotechnology
Category
N/A
Show full summary:
Galectin Therapeutics' Last Stand? Cash Burn and Trial Concerns Raise Red Flags
GALT short: NAVIGATE Phase II/III NASH trial to fail by Dec. Belapectin (fruit pectin IV) doesn't bind galectin-3. Founder's 3rd failed pectin co. Failed Ph2, proceeding on flawed subgroup. Cash until May. Paper published. No personal animus, data will tell truth.
Read full article (2 min)